196 related articles for article (PubMed ID: 12631097)
1. Zoledronic acid to prevent bone loss in the first 6 months after renal transplantation.
Haas M; Leko-Mohr Z; Roschger P; Kletzmayr J; Schwarz C; Mitterbauer C; Steininger R; Grampp S; Klaushofer K; Delling G; Oberbauer R
Kidney Int; 2003 Mar; 63(3):1130-6. PubMed ID: 12631097
[TBL] [Abstract][Full Text] [Related]
2. Effects of bisphosphonates on bone loss in the first year after renal transplantation--a meta-analysis of randomized controlled trials.
Mitterbauer C; Schwarz C; Haas M; Oberbauer R
Nephrol Dial Transplant; 2006 Aug; 21(8):2275-81. PubMed ID: 16574684
[TBL] [Abstract][Full Text] [Related]
3. Zoledronic acid prevents bone loss after liver transplantation: a randomized, double-blind, placebo-controlled trial.
Crawford BA; Kam C; Pavlovic J; Byth K; Handelsman DJ; Angus PW; McCaughan GW
Ann Intern Med; 2006 Feb; 144(4):239-48. PubMed ID: 16490909
[TBL] [Abstract][Full Text] [Related]
4. Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer.
Michaelson MD; Kaufman DS; Lee H; McGovern FJ; Kantoff PW; Fallon MA; Finkelstein JS; Smith MR
J Clin Oncol; 2007 Mar; 25(9):1038-42. PubMed ID: 17369566
[TBL] [Abstract][Full Text] [Related]
5. Nonsustained effect of short-term bisphosphonate therapy on bone turnover three years after renal transplantation.
Schwarz C; Mitterbauer C; Heinze G; Woloszczuk W; Haas M; Oberbauer R
Kidney Int; 2004 Jan; 65(1):304-9. PubMed ID: 14675064
[TBL] [Abstract][Full Text] [Related]
6. Treatment with zoledronic acid ameliorates negative geometric changes in the proximal femur following acute spinal cord injury.
Shapiro J; Smith B; Beck T; Ballard P; Dapthary M; BrintzenhofeSzoc K; Caminis J
Calcif Tissue Int; 2007 May; 80(5):316-22. PubMed ID: 17417700
[TBL] [Abstract][Full Text] [Related]
7. Short-term zoledronic acid treatment increases bone mineral density and marrow clonogenic fibroblast progenitors after allogeneic stem cell transplantation.
Tauchmanovà L; Ricci P; Serio B; Lombardi G; Colao A; Rotoli B; Selleri C
J Clin Endocrinol Metab; 2005 Feb; 90(2):627-34. PubMed ID: 15546907
[TBL] [Abstract][Full Text] [Related]
8. Effects of zoledronic acid on bone fusion in osteoporotic patients after lumbar fusion.
Chen F; Dai Z; Kang Y; Lv G; Keller ET; Jiang Y
Osteoporos Int; 2016 Apr; 27(4):1469-1476. PubMed ID: 26556733
[TBL] [Abstract][Full Text] [Related]
9. The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy.
Israeli RS; Rosenberg SJ; Saltzstein DR; Gottesman JE; Goldstein HR; Hull GW; Tran DN; Warsi GM; Lacerna LV
Clin Genitourin Cancer; 2007 Mar; 5(4):271-7. PubMed ID: 17553207
[TBL] [Abstract][Full Text] [Related]
10. Cyclosporine bone remodeling effect prevents steroid osteopenia after kidney transplantation.
Westeel FP; Mazouz H; Ezaitouni F; Hottelart C; Ivan C; Fardellone P; Brazier M; El Esper I; Petit J; Achard JM; Pruna A; Fournier A
Kidney Int; 2000 Oct; 58(4):1788-96. PubMed ID: 11012914
[TBL] [Abstract][Full Text] [Related]
11. Pamidronate therapy as prevention of bone loss following renal transplantation.
Fan SL; Almond MK; Ball E; Evans K; Cunningham J
Kidney Int; 2000 Feb; 57(2):684-90. PubMed ID: 10652047
[TBL] [Abstract][Full Text] [Related]
12. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer.
Smith MR; Eastham J; Gleason DM; Shasha D; Tchekmedyian S; Zinner N
J Urol; 2003 Jun; 169(6):2008-12. PubMed ID: 12771706
[TBL] [Abstract][Full Text] [Related]
13. Denosumab in treatment-naïve and pre-treated with zoledronic acid postmenopausal women with low bone mass: Effect on bone mineral density and bone turnover markers.
Anastasilakis AD; Polyzos SA; Efstathiadou ZA; Savvidis M; Sakellariou GT; Papatheodorou A; Kokkoris P; Makras P
Metabolism; 2015 Oct; 64(10):1291-7. PubMed ID: 26198440
[TBL] [Abstract][Full Text] [Related]
14. Zoledronic acid versus alendronate for the prevention of bone loss after heart or liver transplantation.
Shane E; Cohen A; Stein EM; McMahon DJ; Zhang C; Young P; Pandit K; Staron RB; Verna EC; Brown R; Restaino S; Mancini D
J Clin Endocrinol Metab; 2012 Dec; 97(12):4481-90. PubMed ID: 23024190
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.
Gnant M; Mlineritsch B; Luschin-Ebengreuth G; Kainberger F; Kässmann H; Piswanger-Sölkner JC; Seifert M; Ploner F; Menzel C; Dubsky P; Fitzal F; Bjelic-Radisic V; Steger G; Greil R; Marth C; Kubista E; Samonigg H; Wohlmuth P; Mittlböck M; Jakesz R;
Lancet Oncol; 2008 Sep; 9(9):840-9. PubMed ID: 18718815
[TBL] [Abstract][Full Text] [Related]
16. Interventions for preventing bone disease in kidney transplant recipients: a systematic review of randomized controlled trials.
Palmer SC; Strippoli GF; McGregor DO
Am J Kidney Dis; 2005 Apr; 45(4):638-49. PubMed ID: 15806466
[TBL] [Abstract][Full Text] [Related]
17. The use of zoledronic acid in men receiving androgen deprivation therapy for prostate cancer with severe osteopenia or osteoporosis.
Campbell SC; Bhoopalam N; Moritz TE; Pandya M; Iyer P; Vanveldhuizen P; Ellis NK; Thottapurathu L; Garewal H; Warren SR; Friedman N; Reda DJ
Urology; 2010 May; 75(5):1138-43. PubMed ID: 20303574
[TBL] [Abstract][Full Text] [Related]
18. Zoledronic acid initiated during the first year of androgen deprivation therapy increases bone mineral density in patients with prostate cancer.
Ryan CW; Huo D; Demers LM; Beer TM; Lacerna LV
J Urol; 2006 Sep; 176(3):972-8; discussion 978. PubMed ID: 16890673
[TBL] [Abstract][Full Text] [Related]
19. Effects of 12 months of recombinant growth hormone therapy on parameters of bone metabolism and bone mineral density in patients on chronic hemodialysis.
Kotzmann H; Riedl M; Pietschmann P; Schmidt A; Schuster E; Kreuzer S; Kainberger F; Frisch H; Geyer G; Hörl WH; Mayer G; Luger A
J Nephrol; 2004; 17(1):87-94. PubMed ID: 15151263
[TBL] [Abstract][Full Text] [Related]
20. Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results.
Bundred NJ; Campbell ID; Davidson N; DeBoer RH; Eidtmann H; Monnier A; Neven P; von Minckwitz G; Miller JC; Schenk NL; Coleman RE
Cancer; 2008 Mar; 112(5):1001-10. PubMed ID: 18205185
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]